Gilead Sciences

The Food and Drug Administration on Thursday approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus.

Pharmaceutical giant Gilead says it plans to charge at least $2,300 for a single treatment course of Remdesivir, a drug shown to shorten recovery time for severely ill coronavirus patients.

Results from a phase three trial show that Remdesivir helps recovery in moderately-ill coronavirus patients.